# US 2008/0317731 A1 · Phospholipases, Nucleic Acids Encoding Them and Methods for Making and Using Them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0317731 A1
- Document ID: US20080317731A1
- Status: Published application
- Kind: A1
- Application number: 10/592,450
- Filed: 2005-03-08
- Published: 2008-12-25
- Earliest claimed: 2004-03-08
- Assignees: Diversa Corporation
- Inventors: Svetlana Gramatikova; Geoff Hazlewood; David Lam; Nelson R. Barton; Blake G. Sturgis; Dan E. Robertson; Jincai Li; Joel A. Kreps; Roderick Fielding; Robert C. Brown; Amit Vasavada; Xuqiu Tan; Andrian Badillo; Wilhelmus P. Van Hoek; Giselle Janssen; Charles Isaac; Mark J. Burk
- Web page: https://patentgrep.com/patent/US20080317731A1

## CPC

- C12N 15/8242: {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
- A61P 3/06: Antihyperlipidemics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- C12N 15/8247: {involving modified lipid metabolism, e.g. seed oil composition}
- C12P 7/6418: by hydrolysis of fatty acid esters
- C12P 7/6458: by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
- C12P 7/6481: Phosphoglycerides (phosphoglycerides having carboxylic acids with less than seven carbon atoms C12P7/62)
- C07K 2319/00: Fusion polypeptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP)) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.

## Claims

### Claim at position 1

1: An isolated, synthetic or recombinant nucleic acid comprising
(i) a nucleic acid having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more or complete sequence identity to
(a) a nucleic acid that encodes the polypeptide having a sequence as set forth in SEQ ID NO:2;
(b) a nucleic acid that encodes the polypeptide having a sequence as set forth in SEQ ID NO:2, but lacking a signal sequence; or, to
(c) SEQ ID NO:1,
wherein the nucleic acid encodes at least one polypeptide having a phospholipase activity;
(ii) a sequence that hybridizes under stringent conditions to SEQ ID NO:1, or to a nucleic acid sequence that encodes the polypeptide having a sequence as set forth in SEQ ID NO:2,
wherein the stringent conditions include a wash step comprising a wash in 0.2×SSC at a temperature of about 65° C. for about 15 minutes,
wherein the nucleic acid encodes at least one polypeptide having a phospholipase activity;
(iii) the nucleic acid of (i), wherein
the sequence identities are determined by analysis with a sequence comparison algorithm comprising a BLAST version 2.2.2 algorithm where a filtering setting is set to blastall-p blastp-d “nr pataa”−F F, and all other options are set to default;
(iv) the nucleic acid of any of (i) to (iii), wherein the nucleic acid encodes: (A) SEQ ID NO:175, which is equivalent to SEQ ID NO:2 minus a leader sequence, and having three (3) amino acid residue changes as compared to SEQ ID NO:2, or, (B) SEQ ID NO:176, which is equivalent to SEQ ID NO:2 but having three (3) amino acid residue changes as compared to SEQ ID NO:2;
(v) the nucleic acid of any of (i) to (iv), wherein the phospholipase activity comprises: catalyzing hydrolysis of a glycerolphosphate ester linkage; catalyzing hydrolysis of an ester linkage in a phospholipid in a vegetable oil or an oilseed phospholipid; a phospholipase C(PLC) activity; a phospholipase A (PLA) activity; a phospholipase B (PLB) activity; a phospholipase D (PLD) activity; a phospholipase D1 or a phospholipase D2 activity; hydrolysis of a glycoprotein; hydrolysis of a glycoprotein in a potato tuber; a patatin enzymatic activity; or, a lipid acyl hydrolase (LAH) activity;
(vi) the nucleic acid of any of (i) to (v), wherein the phospholipase activity comprises a combination of one or more of phospholipase activities, or the phospholipase activity comprises PLC and PLA activity; PLB and PLA activity; PLC and PLD activity; PLC and PLB activity; PLB and patatin activity; PLC and patatin activity; PLD and PLA; PLD, PLA, PLB and PLC activity; or PLD, PLA, PLB, PLC and patatin activity, or the phospholipase activity comprises lysophospholipase (LPL) activity or lysophospholipase-transacylase (LPTA) activity or lysophospholipase (LPL) activity and lysophospholipase-transacylase (LPTA) activity,
(vii) the nucleic acid of any of (i) to (vi), wherein the phospholipase activity comprises catalyzing hydrolysis of a glycerolphosphate ester linkage in phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and/or phosphatidic acid or a combination thereof,
(viii) the nucleic acid of any of (i) to (vii), wherein the phospholipase activity is thermostable, or the polypeptide retains a phospholipase activity under conditions comprising a temperature range of between about 37° C. to about 95° C., or between about 55° C. to about 85° C., or between about 70° C. to about 75° C., or between about 70° C. to about 95° C., or between about 90° C. to about 95° C.;
(ix) the nucleic acid of any of (i) to (viii), wherein the phospholipase activity is thermotolerant, or the polypeptide retains a phospholipase activity after exposure to a temperature in the range from greater than 37° C. to about 95° C., from greater than 55° C. to about 85° C., or between about 70° C. to about 75° C., or from greater than 90° C. to about 95° C.;
(x) the nucleic acid of any of (i) to (ix), wherein the nucleic acid further comprises a heterologous nucleic acid sequence;
(xi) the nucleic acid of (x), wherein the heterologous nucleic acid sequence encodes a heterologous polypeptide;
(xii) the nucleic acid of (xi), wherein the heterologous polypeptide comprises or consists of a signal sequence (a signal peptide), a catalytic domain, a linker sequence, a protease cleavage recognition site, a non-phospholipase enzyme sequence, a phospholipase enzyme sequence; or
(xiii) a nucleic acid comprising a sequence completely (fully) complementary to the nucleic acid sequence of any of (i) to (xii).

### Claim at position 2

2-28. (canceled)

### Claim at position 3 (depends on 1)

29: A probe for identifying or isolating a nucleic acid encoding a polypeptide with a phospholipase activity, wherein the probe comprises
(A) (a) a nucleic acid sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:175 or SEQ ID NO:176, or (b) SEQ ID NO:1, or (c) the nucleic acid of claim 1, wherein the probe identifies the nucleic acid by binding or hybridization, or
(B) the probe of (A), wherein the probe comprises a detectable agent, a radioactive isotope, a fluorescent dye or an enzyme capable of catalyzing the formation of a detectable product.

### Claim at position 4

30-40. (canceled)

### Claim at position 5 (depends on 1)

41: An expression cassette comprising a nucleic acid comprising the sequence of claim 1.

### Claim at position 6 (depends on 1)

42: A vector or a cloning vehicle comprising
(a) a nucleic acid comprising the sequence of claim 1, or
(b) the vector or cloning vehicle of (a), wherein the cloning vehicle comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome, or the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, or the vector or a cloning vehicle comprises or is contained within a bacterial artificial chromosome (BAC), a plasmid, a bacteriophage P1-derived vector (PAC), a yeast artificial chromosome (YAC), or a mammalian artificial chromosome (MAC).

### Claim at position 7

43-45. (canceled)

### Claim at position 8 (depends on 1, 41, 42)

46: A transformed cell comprising
(a) a nucleic acid comprising the sequence of claim 1, or the expression cassette of claim 41, or the vector or cloning vehicle of claim 42, or
(b) the transformed cell of (a), wherein the cell is a bacterial cell, a mammalian cell, a fungal cell, a yeast cell, an insect cell or a plant cell.

### Claim at position 9

47-48. (canceled)

### Claim at position 10 (depends on 1)

49: A transgenic non-human animal comprising
(a) the sequence of claim 1, or
(b) the transgenic non-human animal of (a), wherein the animal is a mouse, a goat, a rabbit, a sheep, a pig or a cow.

### Claim 50

(canceled)

### Claim at position 12 (depends on 1)

51: A transgenic plant or seed comprising
(a) the sequence of claim 1, or
(b) the transgenic plant or seed of (a), wherein the plant is a corn plant, a sorghum plant, a potato plant, a tomato plant, a wheat plant, an oilseed plant, a rapeseed plant, a soybean plant, a rice plant, a barley plant, a grass, a cottonseed, a palm, a sesame plant, a peanut plant, a sunflower plant or a tobacco plant, or
(c) the transgenic plant or seed of (a), wherein the seed is a corn seed, a wheat kernel, an oilseed, a rapeseed, a soybean seed, a palm kernel, a sunflower seed, a sesame seed, a rice, a barley, a peanut, a cottonseed, a palm, a peanut, a sesame seed, a sunflower seed or a tobacco plant seed.

### Claim at position 13

52-54. (canceled)

### Claim at position 14 (depends on 1)

55: An antisense oligonucleotide comprising
(a) a nucleic acid sequence complementary to or capable of hybridizing under stringent conditions to the sequence of claim 1, or
(b) the antisense oligonucleotide of (a), wherein the antisense oligonucleotide is between about 10 to 50, about 20 to 60, about 30 to 70, about 40 to 80, or about 60 to 100 bases in length.

### Claim 56

(canceled)

### Claim at position 16 (depends on 1)

57: A method of inhibiting the translation of a phospholipase message in a cell comprising administering to the cell or expressing in the cell an antisense oligonucleotide comprising a nucleic acid sequence complementary to or capable of hybridizing under stringent conditions to the sequence of claim 1.

### Claim at position 17 (depends on 1)

58: A double-stranded inhibitory RNA (RNAi) molecule comprising
(a) a duplex nucleotide version of the sequence of claim 1, or
(b) the double-stranded inhibitory RNA (RNAi) of (a), wherein the RNAi is about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more duplex nucleotides in length.

### Claim 59

(canceled)

### Claim at position 19 (depends on 58)

60: A method of inhibiting the expression of a phospholipase in a cell comprising administering to the cell or expressing in the cell a double-stranded inhibitory RNA (iRNA), wherein the RNA comprises the double-stranded inhibitory RNA (RNAi) molecule sequence of claim 58.

### Claim at position 20 (depends on 1)

61: An isolated, synthetic or recombinant polypeptide having phospholipase activity or capable of acting as an immunogen to generate an antibody specific for wherein the polypeptide comprises:
(i) an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more or complete sequence identity to the amino acid sequence of SEQ ID NO:2;
(ii) an amino acid sequence encoded by the nucleic acid of any one of claim 1 (i) to claim 1 (xi);
(iii) the amino acid sequence of SEQ ID NO:2 and having at least one amino acid modification selected from the group consisting of N63D, N131S and N134D, or having at least two of the amino acid modifications selected from the group consisting of N63D, N131S and N134;
(iv) comprising the amino acid sequence of (i), (ii) or (iii) and lacking a homologous signal sequence;
(v) comprising the amino acid sequence of (i), (ii), (iii) or (iv) and further comprising a heterologous amino acid sequence;
(vi) comprising the sequence of (v), wherein the heterologous amino acid sequence comprises or consists of a signal sequence (a signal peptide), a catalytic domain, a linker sequence, a protease cleavage recognition site, a non-phospholipase enzyme sequence, a phospholipase enzyme sequence;
(vii) comprising the amino acid sequence of (v) wherein the heterologous sequence amino acid sequence comprises an N-terminal identification peptide or a peptide or protein that increases stability or simplifies purification of the polypeptide, (viii) the amino acid sequence of (i), wherein the sequence identities are determined by analysis with a sequence comparison algorithm comprising a BLAST version 2.2.2 algorithm where a filtering setting is set to blastall-p blastp-d “nr pataa”-F F, and all other options are set to default;
(ix) the amino acid sequence of any of (i) to (viii), wherein the polypeptide comprises a sequence as set forth in: (A) SEQ ID NO:175, which is equivalent to SEQ ID NO:2 minus a leader sequence, and having three (3) amino acid residue changes as compared to SEQ ID NO:2, or, (B) SEQ ID NO:176, which is equivalent to SEQ ID NO:2 but having three (3) amino acid residue changes as compared to SEQ ID NO:2;
(x) the amino acid sequence of any of (i) to (ix), wherein the phospholipase activity comprises: catalyzing hydrolysis of a glycerolphosphate ester linkage; catalyzing hydrolysis of an ester linkage in a phospholipid in a vegetable oil or an oilseed phospholipid; a phospholipase C (PLC) activity; a phospholipase A (PLA) activity; a phospholipase B (PLB) activity; a phospholipase D (PLD) activity; a phospholipase D1 or a phospholipase D2 activity; hydrolysis of a glycoprotein; hydrolysis of a glycoprotein in a potato tuber; a patatin enzymatic activity; or, a lipid acyl hydrolase (LAH) activity;
(xi) the amino acid sequence of any of (i) to (x), wherein the phospholipase activity comprises a combination of one or more of phospholipase activities, or the phospholipase activity comprises PLC and PLA activity; PLB and PLA activity; PLC and PLD activity; PLC and PLB activity; PLB and patatin activity; PLC and patatin activity; PLD and PLA; PLD, PLA, PLB and PLC activity; or PLD, PLA, PLB, PLC and patatin activity, or the phospholipase activity comprises lysophospholipase (LPL) activity or lysophospholipase-transacylase (LPTA) activity or lysophospholipase (LPL) activity and lysophospholipase-transacylase (LPTA) activity,
(xii) the amino acid sequence of any of (i) to (xi), wherein the phospholipase activity comprises catalyzing hydrolysis of a glycerolphosphate ester linkage in phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and/or phosphatidic acid or a combination thereof,
(xiii) the amino acid sequence of any of (i) to (xii), wherein the phospholipase activity is thermostable, or the polypeptide retains a phospholipase activity under conditions comprising a temperature range of between about 37° C. to about 95° C., or between about 55° C. to about 85° C., or between about 70° C. to about 75° C., or between about 70° C. to about 95° C., or between about 90° C. to about 95° C.;
(xiv) the amino acid sequence of any of (i) to (xiii), wherein the phospholipase activity is thermotolerant, or the polypeptide retains a phospholipase activity after exposure to a temperature in the range from greater than 37° C. to about 95° C., from greater than 55° C. to about 85° C., or between about 70° C. to about 75° C., or from greater than 90° C. to about 95° C.;
(xv) the amino acid sequence of any of (i) to (xiv), wherein the phospholipase activity comprises a specific activity at about 37° C. in the range from about 10 to about 100 units per milligram, from about 100 to about 1000 units per milligram of protein, from about 500 to about 750 units per milligram of protein, from about 500 to about 1200 units per milligram of protein, or from about 750 to about 1000 units per milligram of protein;
(xvi) the amino acid sequence of any of (i) to (xiv), wherein the thermotolerance comprises retention of at least half of the specific activity of the phospholipase at 37° C. after being heated to an elevated temperature;
(xvii) the amino acid sequence of any of (i) to (xvi), wherein the thermotolerance comprises retention of specific activity at 37° C. in the range from about 500 to about 1200 units per milligram of protein after being heated to an elevated temperature;
(xviii) the amino acid sequence of any of (i) to (xvi), wherein the polypeptide comprises at least one glycosylation site, and optionally the glycosylation is an N-linked glycosylation, or the polypeptide is glycosylated after being expressed in an P. pastoris or an S. pombe;
(xix) the amino acid sequence of any of (i) to (xix), wherein the polypeptide retains a phospholipase activity under conditions comprising about pH 6.5, pH 6.0, pH 5.5, 5.0, pH 4.5 or 4.0, or more acidic;
(xx) the amino acid sequence of any of (i) to (xix), wherein the polypeptide retains a phospholipase activity under conditions comprising about pH 7.5, pH 8.0, pH 8.5, pH 9, pH 9.5, pH 10 or pH 10.5, or more basic; or
(xxi) the amino acid sequence of any of (i) to (xx), wherein the polypeptide comprises at least one modification comprising or consisting of an acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphatidylinositol, cross-linking cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of an amino acid or arginylation.

### Claim at position 21

62-92. (canceled)

### Claim at position 22 (depends on 61)

93: A protein preparation comprising the polypeptide of claim 61, wherein the protein preparation comprises a buffer, a liquid, a solid or a gel.

### Claim at position 23 (depends on 61)

94: A heterodimer comprising
(a) the polypeptide of claim 61 and a second domain, or
(b) the heterodimer of (a), wherein the second domain is a polypeptide and the heterodimer is a fusion protein, or the second domain comprises an epitope or a tag.

### Claim at position 24

95-96. (canceled)

### Claim at position 25 (depends on 61)

97: A homodimer comprising the polypeptide of claim 61.

### Claim at position 26 (depends on 61)

98: An immobilized polypeptide, wherein the polypeptide comprises (a) the polypeptide of claim 61; or
(b) the immobilized polypeptide of (a), wherein the polypeptide is immobilized on a cell, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel, a plate, an array or a capillary tube.

### Claim 99

(canceled)

### Claim at position 28 (depends on 1, 61)

100: An array comprising the immobilized polypeptide of claim 61, or an immobilized nucleic acid, wherein the nucleic acid comprises the sequence of claim 1, or a combination thereof.

### Claim 101

(canceled)

### Claim at position 30 (depends on 61)

102: An isolated, synthetic or recombinant antibody that specifically binds to the polypeptide of claim 61, and optionally the antibody is a monoclonal or a polyclonal antibody.

### Claim 103

(canceled)

### Claim at position 32 (depends on 61)

104: A hybridoma comprising an antibody that specifically binds to the polypeptide of claim 61.

### Claim at position 33 (depends on 102)

105: A method of isolating or identifying a polypeptide with a phospholipase activity comprising the steps of:
(a) providing the antibody of claim 102;
(b) providing a sample comprising polypeptides; and
(c) contacting the sample of step (b) with the antibody of step (a) under conditions wherein the antibody can specifically bind to the polypeptide, thereby isolating or identifying a polypeptide having a phospholipase activity.

### Claim at position 34 (depends on 1, 61)

106: A method of making an anti-phospholipase antibody comprising (a) administering to a non-human animal the nucleic acid of claim 1 in an amount sufficient to generate a humoral immune response, thereby making an anti-phospholipase antibody, or, (b) administering to a non-human animal the polypeptide of claim 61 in an amount sufficient to generate a humoral immune response, thereby making an anti-phospholipase antibody.

### Claim 107

(canceled)

### Claim at position 36 (depends on 1)

108: A method of producing a recombinant polypeptide comprising:
(A) (a) providing a nucleic acid operably linked to a promoter, wherein the nucleic acid comprises the sequence of claim 1; and (b) expressing the nucleic acid of step (a) under conditions that allow expression of the polypeptide, thereby producing a recombinant polypeptide, or
(B) the method of (A), wherein the method further comprises transforming a host cell with the nucleic acid of step (a) followed by expressing the nucleic acid of step (a), thereby producing a recombinant polypeptide in a transformed cell.

### Claim 109

(canceled)

### Claim at position 38 (depends on 65)

110: A method for identifying a polypeptide having a phospholipase activity comprising:
(a) providing the polypeptide of claim 65;
(b) providing a phospholipase substrate; and
(c) contacting the polypeptide with the substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of a reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product detects a polypeptide having a phospholipase activity.

### Claim at position 39 (depends on 65)

111: A method for identifying a phospholipase substrate comprising:
(a) providing the polypeptide of claim 65;
(b) providing a test substrate; and
(c) contacting the polypeptide of step (a) with the test substrate of step (b) and detecting a decrease in the amount of substrate or an increase in the amount of reaction product, wherein a decrease in the amount of the substrate or an increase in the amount of a reaction product identifies the test substrate as a phospholipase substrate; or,

### Claim at position 40 (depends on 1, 61)

112: A method of determining whether a test compound specifically binds to a polypeptide comprising:
(i) (a) expressing a nucleic acid or a vector comprising the nucleic acid under conditions permissive for translation of the nucleic acid to a polypeptide, wherein the nucleic acid has the sequence of claim 1;
(b) providing a test compound;
(c) contacting the polypeptide with the test compound; and
(d) determining whether the test compound of step (b) specifically binds to the polypeptide; or,
(ii) (a) providing the polypeptide of claim 61;
(b) providing a test compound;
(c) contacting the polypeptide with the test compound; and
(d) determining whether the test compound of step (b) specifically binds to the polypeptide.

### Claim 113

(canceled)

### Claim at position 42 (depends on 61)

114: A method for identifying a modulator of a phospholipase activity comprising:
(A) (a) providing the polypeptide of claim 61;
(b) providing a test compound;
(c) contacting the polypeptide of step (a) with the test compound of step (b) and measuring an activity of the phospholipase, wherein a change in the phospholipase activity measured in the presence of the test compound compared to the activity in the absence of the test compound provides a determination that the test compound modulates the phospholipase activity, or
(B) the method of (A), wherein the phospholipase activity is measured by providing a phospholipase substrate and detecting a decrease in the amount of the substrate or an increase in the amount of a reaction product, or, an increase in the amount of the substrate or a decrease in the amount of a reaction product, or
(C) the method of (B), wherein a decrease in the amount of the substrate or an increase in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an activator of phospholipase activity, or
(D) the method of (B), wherein an increase in the amount of the substrate or a decrease in the amount of the reaction product with the test compound as compared to the amount of substrate or reaction product without the test compound identifies the test compound as an inhibitor of phospholipase activity.

### Claim at position 43

115-117. (canceled)

### Claim at position 44 (depends on 1, 61)

118: A computer system comprising (A) a processor and a data storage device wherein said data storage device has stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises the sequence of claim 61, a polypeptide encoded by the nucleic acid of claim 1, or
(B) the computer system of (A), wherein the computer system further comprises a sequence comparison algorithm and a data storage device having at least one reference sequence stored thereon, or
(C) the computer system of (B), wherein the sequence comparison algorithm comprises a computer program that indicates polymorphisms, or
(D) the computer system of any of (A) to (C), wherein the computer system further comprises an identifier that identifies one or more features in said sequence.

### Claim at position 45

119-121. (canceled)

### Claim at position 46 (depends on 1, 61)

122: A computer readable medium having stored thereon a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises the polypeptide of claim 61; a polypeptide encoded by the nucleic acid of claim 1.

### Claim at position 47 (depends on 1, 61)

123: A method for identifying a feature in a sequence comprising: (a) reading the sequence using a computer program which identifies one or more features in a sequence, wherein the sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises the polypeptide of claim 61; a polypeptide encoded by the nucleic acid of claim 1; and (b) identifying one or more features in the sequence with the computer program.

### Claim at position 48 (depends on 1, 61)

124: A method for comparing a first sequence to a second sequence comprising:
(A) (a) reading the first sequence and the second sequence through use of a computer program which compares sequences, wherein the first sequence comprises a polypeptide sequence or a nucleic acid sequence, wherein the polypeptide sequence comprises the polypeptide of claim 61 or a polypeptide encoded by the nucleic acid of claim 1; and (b) determining differences between the first sequence and the second sequence with the computer program, or
(B) the computer system of (A), wherein the step of determining differences between the first sequence and the second sequence further comprises the step of identifying polymorphisms, or
(C) the computer system of (A) or (B), wherein the method further comprises an identifier that identifies one or more features in a sequence, or
(D) the computer system of any of (A) to (C), wherein the method further comprises reading the first sequence using a computer program and identifying one or more features in the sequence.

### Claim at position 49

125-127. (canceled)

### Claim at position 50 (depends on 1, 31)

128: A method for isolating or recovering a nucleic acid encoding a polypeptide with a phospholipase activity from a sample comprising the steps of:
(A) (a) providing the amplification primer sequence pair of claim 31;
(b) isolating a nucleic acid from the sample or treating the sample such that nucleic acid in the sample is accessible for hybridization to the amplification primer pair; and,
(c) combining the nucleic acid of step (b) with the amplification primer pair of step (a) and amplifying nucleic acid from the sample, thereby isolating or recovering a nucleic acid encoding a polypeptide with a phospholipase activity from the sample; or,
(B) (a) providing a polynucleotide probe comprising the sequence of claim 1;
(b) isolating a nucleic acid from the sample or treating the sample such that nucleic acid in the sample is accessible for hybridization to a polynucleotide probe of step (a);
(c) combining the isolated nucleic acid or the treated sample of step (b) with the polynucleotide probe of step (a); and
(d) isolating a nucleic acid that specifically hybridizes with the polynucleotide probe of step (a), thereby isolating or recovering a nucleic acid encoding a polypeptide with a phospholipase activity from the sample, or
(C) the method of (A) or (B), wherein the sample comprises an environmental sample, or
(D) the method of (C), wherein the environmental sample comprises a water sample, a liquid sample, a soil sample, an air sample or a biological sample, or
(E) the method of (D), wherein the biological sample is derived from a bacterial cell, a protozoan cell, an insect cell, a yeast cell, a plant cell, a fungal cell or a mammalian cell.

### Claim at position 51

129-132. (canceled)

### Claim at position 52 (depends on 1)

133: A method of generating a variant of a nucleic acid encoding a polypeptide with a phospholipase activity comprising:
(A) (a) providing a template nucleic acid comprising a sequence as set forth in claim 1; and
(b) modifying, deleting or adding one or more nucleotides in the template sequence, or a combination thereof, to generate a variant of the template nucleic acid, or
(B) the method of (A), wherein the method further comprises expressing the variant nucleic acid to generate a variant phospholipase polypeptide, or
(C) the method of (A) or (B), wherein the modifications, additions or deletions are introduced by a method comprising error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, Gene Site Saturation Mutagenesis (GSSM), synthetic ligation reassembly (SLR), recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation or a combination thereof, or
(D) the method of and of (A) to (C), wherein the method is iteratively repeated until a variant phospholipase having an altered or different activity or an altered or different stability from that of a polypeptide encoded by the template nucleic acid is produced, or
(E) the method of (D), wherein the variant phospholipase polypeptide is thermotolerant, and retains some activity after being exposed to an elevated temperature, or
(F) the method of (D), wherein the variant phospholipase polypeptide has increased glycosylation as compared to the phospholipase encoded by a template nucleic acid, or
(G) the method of (D), wherein the variant phospholipase polypeptide has a phospholipase activity under a high temperature, wherein the phospholipase encoded by the template nucleic acid is not active under the high temperature, or
(H) the method of (A), wherein the method is iteratively repeated until a phospholipase coding sequence having an altered codon usage from that of the template nucleic acid is produced, or
(I) the method of (A), wherein the method is iteratively repeated until a phospholipase gene having higher or lower level of message expression or stability from that of the template nucleic acid is produced.

### Claim at position 53

134-142. (canceled)

### Claim at position 54 (depends on 1)

143: A method for modifying codons in a nucleic acid encoding a polypeptide with a phospholipase activity to increase its expression in a host cell, the method comprising:
(A) (a) providing a nucleic acid encoding a polypeptide with a phospholipase activity comprising the nucleic acid of claim 1; and,
(b) identifying a non-preferred or a less preferred codon in the nucleic acid of step (a) and replacing it with a preferred or neutrally used codon encoding the same amino acid as the replaced codon, wherein a preferred codon is a codon over-represented in coding sequences in genes in the host cell and a non-preferred or less preferred codon is a codon under-represented in coding sequences in genes in the host cell, thereby modifying the nucleic acid to increase its expression in a host cell; or,
(B) (a) providing a nucleic acid encoding a polypeptide with a phospholipase activity comprising the sequence of claim 1; and,
(b) identifying a codon in the nucleic acid of step (a) and replacing it with a different codon encoding the same amino acid as the replaced codon, thereby modifying codons in a nucleic acid encoding a phospholipase, or
(C) the method of (A) or (B), wherein the host cell is a bacterial cell, a fungal cell, an insect cell, a yeast cell, a plant cell or a mammalian cell.

### Claim at position 55

144-147. (canceled)

### Claim at position 56

148: A method for producing a library of nucleic acids encoding a plurality of modified phospholipase active sites or substrate binding sites, wherein the modified active sites or substrate binding sites are derived from a first nucleic acid comprising a sequence encoding a first active site or a first substrate binding site the method comprising:
(A) (a) providing a first nucleic acid encoding a first active site or first substrate binding site, wherein the first nucleic acid sequence comprises a sequence that hybridizes under stringent conditions to a sequence that encodes a polypeptide having a sequence as set forth in SEQ ID NO:2; SEQ ID NO:175, or SEQ ID NO:176, or (b) SEQ ID NO:1, and the nucleic acid encodes a phospholipase active site or a phospholipase substrate binding site;
(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and,
(c) using the set of mutagenic oligonucleotides to generate a set of active site-encoding or substrate binding site-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized, thereby producing a library of nucleic acids encoding a plurality of modified phospholipase active sites or substrate binding sites, or
(B) the method of (A), wherein the method further comprises mutagenizing the first nucleic acid of step (a) by a method comprising an optimized directed evolution system, Gene Site Saturation Mutagenesis (GSSM), a synthetic ligation reassembly (SLR), error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis, site-specific mutagenesis, gene reassembly, recombination, recursive sequence recombination, phosphothioate-modified DNA mutagenesis, uracil-containing template mutagenesis, gapped duplex mutagenesis, point mismatch repair mutagenesis, repair-deficient host strain mutagenesis, chemical mutagenesis, radiogenic mutagenesis, deletion mutagenesis, restriction-selection mutagenesis, restriction-purification mutagenesis, artificial gene synthesis, ensemble mutagenesis, chimeric nucleic acid multimer creation, or a combination thereof.

### Claim at position 57

149-163. (canceled)

### Claim at position 58 (depends on 61)

164: An isolated, synthetic or recombinant signal sequence consisting of a sequence as set forth in residues 1 to 16, 1 to 17, 1 to 18, 1 to 19, 1 to 20, 1 to 21, 1 to 22, 1 to 23, 1 to 24, 1 to 25, 1 to 26, 1 to 27, 1 to 28, 1 to 28, 1 to 30 or 1 to 31, 1 to 32 or 1 to 33 of SEQ ID NO:2 or the sequence of claim 61.

### Claim at position 59 (depends on 164)

165: A chimeric polypeptide comprising
(a) at least a first domain comprising signal peptide (SP) having a sequence as set forth in claim 164, and at least a second domain comprising a heterologous polypeptide or peptide, wherein the heterologous polypeptide or peptide is not naturally associated with the signal peptide (SP), or
(b) the chimeric polypeptide of (a), wherein the heterologous polypeptide or peptide is not a phospholipase.

### Claim 166

(canceled)

### Claim at position 61 (depends on 164)

167: An isolated, synthetic or recombinant nucleic acid encoding a chimeric polypeptide, wherein the chimeric polypeptide comprises at least a first domain comprising signal peptide (SP having a sequence as set forth in claim 164 and at least a second domain comprising a heterologous polypeptide or peptide, wherein the heterologous polypeptide or peptide is not naturally associated with the signal peptide (SP).

### Claim at position 62 (depends on 1, 61)

168: A method of increasing thermotolerance or thermostability of a phospholipase polypeptide, the method comprising glycosylating a phospholipase, wherein the polypeptide comprises at least thirty contiguous amino acids of the polypeptide of claim 61, or a polypeptide encoded by the nucleic acid of claim 1, thereby increasing the thermotolerance or thermostability of the phospholipase.

### Claim at position 63 (depends on 1)

169: A method for overexpressing a recombinant phospholipase in a cell comprising expressing a vector comprising the nucleic acid of claim 1, wherein overexpression is effected by use of a high activity promoter, a dicistronic vector or by gene amplification of the vector.

### Claim at position 64

170-174. (canceled)

### Claim at position 65 (depends on 1, 61)

175: A method for hydrolyzing, breaking up or disrupting a phospholipid-comprising composition comprising:
(A) (a) providing the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing a composition comprising a phospholipid; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the phospholipase hydrolyzes, breaks up or disrupts the phospholipid-comprising composition, or
(B) the method of (A), wherein the composition comprises a phospholipid-comprising lipid bilayer or membrane, and optionally the composition comprises a plant cell, a bacterial cell, a yeast cell, an insect cell, or an animal cell, or
(C) the method of (A), wherein the method comprises use of high shear mixing of the composition, followed by no or low shear mixing with the at least one polypeptide of the invention having a phospholipase activity to allow adequate contacting of the phospholipid substrate with the phospholipase.

### Claim at position 66

176-177. (canceled)

### Claim at position 67 (depends on 1, 61)

178: A method for liquefying or removing a phospholipid-comprising composition comprising:
(a) providing the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing a composition comprising a phospholipid; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the phospholipase removes or liquefies the phospholipid-comprising composition.

### Claim at position 68 (depends on 1, 61)

179: A detergent composition comprising
(a) the polypeptide of claim 61, or a polypeptide encoded by the nucleic acid of claim 1, wherein the polypeptide has a phospholipase activity, or
(b) the detergent of (a), wherein the phospholipase is a nonsurface-active phospholipase or a surface-active phospholipase, or the phospholipase is formulated in a non-aqueous liquid composition, a cast solid, a lyophilized powder, a granular form, a particulate form, a compressed tablet, a pellet, a gel form, a paste, an aerosol, or a slurry form.

### Claim at position 69

180-181. (canceled)

### Claim at position 70 (depends on 1, 61)

182: A method for washing an object comprising:
(a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing an object; and
(c) contacting the polypeptide of step (a) and the object of step (b) under conditions wherein the composition can wash the object.

### Claim at position 71 (depends on 1, 61)

183: A method for degumming an oil comprising:
(A) (a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing an composition comprising an phospholipid-containing fat or oil; and
(c) contacting the polypeptide of step (a) and the composition of step (b) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition, or
(B) the method of (A), wherein the oil-comprising composition comprises a plant, an animal, an algae or a fish oil or fat, and optionally the plant oil comprises a rice bran oil, a soybean oil, a rapeseed oil, a corn oil, an oil from a palm kernel, a canola oil, a sunflower oil, a sesame oil or a peanut oil, or
(C) the method of (A) or (B), wherein the polypeptide hydrolyzes a phosphatide from a hydratable and/or a non-hydratable phospholipid in the oil-comprising composition, or optionally the polypeptide hydrolyzes a phosphatide at a glyceryl phosphoester bond to generate a diglyceride and water-soluble phosphate compound, or
(D) the method of any of (A) to (C), wherein the polypeptide has a phospholipase C activity, or optionally the polypeptide has a phospholipase D activity and a phosphatase enzyme is also added, and optionally the polypeptide having a phospholipase activity has a PLC activity and the method increases neutral oils, and optionally the polypeptide having a phospholipase activity has a PLC activity and the method increases diacylglycerol (DAG) production to contribute to an oil phase, or
(E) the method of any of (A) to (D), wherein the contacting comprises hydrolysis of a hydrated phospholipid in an oil, or
(F) the method of any of (A) to (E), wherein the hydrolysis conditions of step
(c) comprise a temperature of about 20° C. to 40° C. at an alkaline pH, or optionally the alkaline conditions comprise a pH of about pH 8 to pH 10, or
(G) the method of any of (A) to (F), wherein the hydrolysis conditions comprise an alkaline pH, or the hydrolysis conditions of step (c) comprise a reaction time of about 3 to 10 minutes, or the hydrolysis conditions of step (c) comprise hydrolysis of hydratable and non-hydratable phospholipids in oil at a temperature of about 50° C. to 60° C., at a pH of about pH 5 to pH 6.5, at a pH of about pH 6.0 to pH 7.5, or at a pH of about pH 5 to pH 8.0, using a reaction time of about 30 to 60 minutes, or the alkaline conditions are sufficient to cause isomerization of a 1,2-DAG produced by a PLC into a 1,3-DAG, or
(H) the method of any of (A) to (G), wherein the polypeptide is bound to a filter and the phospholipid-containing fat or oil is passed through the filter, or optionally the polypeptide is added to a solution comprising the phospholipid-containing fat or oil and then the solution is passed through a filter, or
(I) the method of (A) or (H), wherein the method further comprises addition of one or more polypeptides having a protease, an amylase, a lipase, a cutinase, another phospholipase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a lactase, and/or a peroxidase, or polypeptides with equivalent activity, or a combination thereof, to further break down gum mass and enhance oil yields, or
(J) the method of any of (A) to (I), wherein the method further comprises physical removal of gum produced by the degumming method by addition of a hardening substance, or
(K) the method of (J), wherein the final degummed oil product is enriched in 1,3-DAG, or
(L) the method of any of (K), wherein the final degummed oil product comprises not less than 1.0% 1,3-DAG.

### Claim at position 72

184-196. (canceled)

### Claim at position 73 (depends on 1, 61)

197: A method for converting a non-hydratable phospholipid to a hydratable form comprising:
(A) (a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing an composition comprising a non-hydratable phospholipid; and
(c) contacting the polypeptide of step (a) and the composition of step (b) under conditions wherein the polypeptide converts the non-hydratable phospholipid to a hydratable form, or
(B) the method of (A), wherein the polypeptide has a phospholipase C activity, or optionally the polypeptide has a phospholipase D activity and a phosphatase enzyme is also added.

### Claim at position 74

198-199. (canceled)

### Claim at position 75 (depends on 1, 61)

200: A method for caustic refining of a phospholipid-containing composition comprising:
(A) (a) providing a composition comprising a polypeptide having a phospholipase activity, wherein the polypeptide has the sequence of claim 61, or comprises a polypeptide encoded by the nucleic acid of claim 1;
(b) providing an composition comprising a phospholipid; and
(c) contacting the polypeptide of step (a) with the composition of step (b) before, during or after the caustic refining, or
(B) the method of (A), wherein the polypeptide has a phospholipase C activity, or
(C) the method of (A) or (B), wherein the polypeptide having a phospholipase activity is added before addition of acid or caustic, or the polypeptide having a phospholipase activity is added during caustic refining and varying levels of acid and caustic are added depending on levels of phosphorus and levels of free fatty acids, or the polypeptide having a phospholipase activity is added after caustic refining: in an intense mixer or retention mixer prior to separation; following a heating step; in a centrifuge; in a soapstock; in a washwater; or, during bleaching or deodorizing steps, or
(D) the method of (C), wherein the caustic refining conditions are generated by addition of a concentrated solution of caustic, and optionally the concentrated solution of caustic is more concentrated than the industrial standard of 11%, and optionally the concentrated solution of caustic is between about 12% and 50% concentrated, or
(E) the method of any of (A) to (D), wherein
the composition comprising the phospholipid comprises a plant, and optionally the polypeptide is expressed transgenically in the plant, and optionally the polypeptide having a phospholipase activity added during crushing of a seed or other plant part, or, the polypeptide having a phospholipase activity added following crushing or prior to refining, or
(F) the method of any of (A) to (E), wherein the method comprises a process as set forth in FIG. 13.

### Claim at position 76

201-204. (canceled)

### Claim at position 77 (depends on 1, 61)

205: A method for purification of a phytosterol or a triterpene comprising:
(A) (a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing an composition comprising a phytosterol or a triterpene; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition, or
(B) the method of (A), wherein the polypeptide has a phospholipase C activity, or
(C) the method of (A) or (B), wherein the phytosterol or a triterpene comprises a plant sterol, or
(D) the method of any of (A) to (C), wherein the plant sterol is derived from a vegetable oil, or
(E) the method of (D), wherein the vegetable oil comprises a coconut oil, canola oil, cocoa butter oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, oil derived from a rice bran, safflower oil, sesame oil, soybean oil or a sunflower oil, or
(F) the method of any of (A) to (E), wherein the method further comprises use of nonpolar solvents to quantitatively extract free phytosterols and phytosteryl fatty-acid esters, or
(G) the method of any of (A) to (F), wherein the phytosterol or a triterpene comprises a β-sitosterol, a campesterol, a stigmasterol, a stigmastanol, a β-sitostanol, a sitostanol, a desmosterol, a chalinasterol, a poriferasterol, a clionasterol or a brassicasterol.

### Claim at position 78

206-211. (canceled)

### Claim at position 79 (depends on 1, 61)

212: A method for refining a crude oil comprising:
(A) (a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing a composition comprising an oil comprising a phospholipid; and
(c) contacting the polypeptide of step (a) with the composition of step (b) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition, or
(B) the method of (A), wherein the polypeptide has a phospholipase C activity, or
(C) the method of (A) or (B), wherein the polypeptide having a phospholipase activity is in a water solution that is added to the composition, or the water level is between about 0.5 to 5%, or the process time is less than about 2 hours, or the process time is less than about 60 minutes, or the process time is less than about 30 minutes, less than about 15 minutes, or less than about 5 minutes, or
(D) the method of any of (A) to (C), wherein the hydrolysis conditions comprise a temperature of between about 25° C.-70° C., or the hydrolysis conditions comprise use of caustics, or the hydrolysis conditions comprise a pH of between about pH 3 and pH 10, or the hydrolysis conditions comprise addition of emulsifiers and/or mixing after the contacting of step (c), or
(E) the method of any of (A) to (D), wherein the method further comprises addition of an emulsion-breaker and/or heat or cooling to promote separation of an aqueous phase, or
(F) the method of any of (A) to (E), wherein the method further comprises degumming before the contacting step to collect lecithin by centrifugation and then adding a PLC, a PLC and/or a PLA to remove non-hydratable phospholipids, or
(G) the method of any of (A) to (F), wherein the method further comprises water degumming of crude oil to less than 10 ppm phosphorus for edible oils and subsequent physical refining to less than about 50 ppm phosphorus for biodiesel oils, or
(H) the method of any of (A) to (G), wherein the method further comprises addition of acid to promote hydration of non-hydratable phospholipids, or
(I) the method of any of (A) to (I), wherein sufficient acid is added to promote lowering of the calcium and magnesium metal content.

### Claim at position 80

213-226. (canceled)

### Claim at position 81 (depends on 1, 61)

227: A method for degumming an oil or a fat comprising:
(a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1, wherein the phospholipase activity comprises a phospholipase D activity, and a phosphatase enzyme;
(b) providing an composition comprising an phospholipid-containing fat or oil; and
(c) contacting the polypeptide of step (a) and the composition of step (b) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition.

### Claim at position 82 (depends on 1, 61)

228: A composition having the equivalent of a phospholipase C activity comprising providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1, wherein the phospholipase activity comprises a phospholipase D activity, and a phosphatase enzyme.

### Claim at position 83 (depends on 1, 61)

229: A method for ameliorating or preventing lipopolysaccharide (LPS)-mediated toxicity comprising administering to a patient a pharmaceutical composition comprising the polypeptide of claim 61, or a polypeptide encoded by the nucleic acid of claim 1.

### Claim at position 84 (depends on 1, 61)

230: A method for detoxifying an endotoxin comprising contacting the endotoxin with the polypeptide of claim 61, or a polypeptide encoded by the nucleic acid of claim 1.

### Claim at position 85 (depends on 1, 61)

231: A method for deacylating a 2′ or a 3′ fatty acid chain from a lipid A comprising contacting
(A) the lipid A with the polypeptide of claim 61, or a polypeptide encoded by the nucleic acid of claim 1, or
(B) the method of (A), wherein the polypeptide has a patatin activity, or
(C) the method of (B), wherein the patatin has a sequence as set forth in SEQ ID NO:12 (encoded by SEQ ID NO:11), SEQ ID NO:14 (encoded by SEQ ID NO:13), SEQ ID NO:18 (encoded by SEQ ID NO:17), SEQ ID NO:26 (encoded by SEQ ID NO:25), SEQ ID NO:28 (encoded by SEQ ID NO:27), SEQ ID NO:34 (encoded by SEQ ID NO:33), SEQ ID NO:36 (encoded by SEQ ID NO:35), SEQ ID NO:44 (encoded by SEQ ID NO:43), SEQ ID NO:46 (encoded by SEQ ID NO:45), SEQ ID NO:56 (encoded by SEQ ID NO:55), SEQ ID NO:60 (encoded by SEQ ID NO:59), SEQ ID NO:66 (encoded by SEQ ID NO:65), SEQ ID NO:72 (encoded by SEQ ID NO:71), SEQ ID NO:78 (encoded by SEQ ID NO:77), SEQ ID NO:87 (encoded by SEQ ID NO:86), SEQ ID NO:88 (encoded by SEQ ID NO:87), SEQ ID NO:92 (encoded by SEQ ID NO:91), SEQ ID NO:96 (encoded by SEQ ID NO:95), SEQ ID NO:100 (encoded by SEQ ID NO:99), SEQ ID NO:104 (encoded by SEQ ID NO:103), SEQ ID NO:126 (encoded by SEQ ID NO:125), SEQ ID NO:128 (encoded by SEQ ID NO:127), SEQ ID NO:132 (encoded by SEQ ID NO:131), SEQ ID NO:134 (encoded by SEQ ID NO:133), SEQ ID NO:136 (encoded by SEQ ID NO:135), or SEQ ID NO:138 (encoded by SEQ ID NO:137).

### Claim at position 86

232-250. (canceled)

### Claim at position 87 (depends on 1, 61)

251: A process for reducing gum mass and increasing neutral oil (triglyceride) gain through reduced oil entrapment comprising:
(A) (a) providing a composition comprising the polypeptide having a phospholipase activity of claim 61, or a polypeptide encoded by the nucleic acid of claim 1;
(b) providing an composition comprising an phospholipid-containing fat or oil; and
(c) contacting the polypeptide of step (a) and the composition of step (b) under conditions wherein the polypeptide can catalyze the hydrolysis of a phospholipid in the composition for a time sufficient to reduce gum mass and increase neutral oils, or
(B) the method of (A), wherein the protein preparation comprises a formulation comprising a non-aqueous liquid composition, a cast solid, a powder, a lyophilized powder, a granular form, a particulate form, a compressed tablet, a pellet, a pill, a gel form, a hydrogel, a paste, an aerosol, a spray, a lotion, a slurry formulation, an aqueous/oil emulsion, a cream, a capsule, a vesicle, or a micellar suspension.

### Claim at position 88

252-262. (canceled)

### Claim at position 89 (depends on 1)

263: A method for making a variant phospholipase coding sequence having increased expression in a host cell comprising modifying the nucleic acid sequence of claim 1 such that one, several or all N-linked glycosylation site motifs in the phospholipase are modified to a non-glycosylated motif in the variant phospholipase.

### Claim 264

(canceled)

### Claim at position 91 (depends on 2, 61)

265: A method for making a variant phospholipase coding sequence encoding a phospholipase having increased resistance to a protease comprising modifying position 131 of SEQ ID NO:2, or an amino acid equivalent to position 131 in the amino acid sequence of claim 61, 2 to one, several or all of the following residues: Lysine (K); Serine (S); Glycine (G); Arginine (R); Glutamine (Q); Alanine (A); Isoleucine (I); Histidine (H); Phenylalanine (F); Threonine (T); Methionine (M) Leucine (L).

### Claim 266

(canceled)

### Claim at position 93 (depends on 2, 61)

267: A method for making a variant phospholipase coding sequence encoding a phospholipase having decreased resistance to a protease comprising modifying position 131 of SEQ ID NO:2, or an amino acid equivalent to position 131 in the amino acid sequence of claim 61, 2 to one, several or all of the following residues: Tryptophan (W); Glutamate (E); Tyrosine (Y).

### Claim 268

(canceled)

### Claim at position 95 (depends on 1, 61)

269: A method for making and expressing a protein having a biological activity whose activity is temporarily inactivated by glycosylation comprising:
(A) (a) providing a nucleic acid encoding a protein having a biological activity, wherein the protein is not naturally glycosylated, and the polypeptide comprises the polypeptide of claim 61, or comprises a polypeptide encoded by the nucleic acid of claim 1;
(b) inserting at least one glycosylation motif coding sequence into the protein-encoding nucleic acid, wherein the glycosylated form of the protein is inactive;
(c) inserting a targeting sequence into the protein such that it is directed to a host cell's secretory pathway, wherein the host cell is capable of recognizing the glycosylation motif and glycosylating the protein; and
(d) expressing the modified nucleic acid in the host cell, or
(B) the method of (A), wherein the method further comprises deglycosylating the expressed the protein, thereby re-activating the activity of the protein, or
(C) the method of (A) or (B), wherein the host cell is a eukaryotic cell.

### Claim at position 96

270-271. (canceled)

### Claim at position 97 (depends on 1)

272: A method for expressing phospholipase C comprising
(A) (a) providing a Pichia strain with a Mut+phenotype;
(b) inserting a heterologous phospholipase C-encoding nucleic acid in the Pichia strain, wherein the phospholipase C-encoding nucleic acid comprises the nucleic acid of claim 1; and,
(c) culturing the Pichia strain under conditions whereby the phospholipase C is expressed, or
(B) the method of (A), wherein the method further comprises supplementing the culture conditions with zinc.

### Claim 273

(canceled)

### Claim at position 99 (depends on 1)

274: A cell system for expressing phospholipase C comprising a Mut+phenotype Pichia strain comprising a heterologous phospholipase C-encoding nucleic acid operably linked to a promoter operable in the Pichia strain, wherein the phospholipase C-encoding nucleic acid comprises the nucleic acid of claim 1.

### Claim at position 100 (depends on 1, 61)

275: A cell system for expressing a heterologous protein comprising a Pichia strain cell resistant to zeocin, wherein the heterologous protein is encoded by a nucleic acid comprising the nucleic acid of claim 1, or the heterologous protein comprises the polypeptide of claim 61.

### Claim at position 101 (depends on 1)

276: A zeocin-resistant yeast cell system for expressing a heterologous protein comprising the steps of
(A) (a) providing a Pichia sp. cell comprising a heterologous nucleic acid capable of expressing a heterologous protein, wherein the heterologous protein-encoding nucleic acid comprises the nucleic acid of claim 1;
(b) culturing the cell under conditions comprising zeocin at an initial concentration;
(c) selecting cells resistant to the initial concentration of zeocin, and reculturing under conditions comprising a higher concentration of zeocin; and
(d) selecting the cells cultured in step (c) resistant to the higher concentration of zeocin or
(B) the method of (A), wherein the heterologous protein is an enzyme, or
(C) the method of (B), wherein the enzyme is a phospholipase, or a phospholipase C (PLC).

### Claim 277

(canceled)
